You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension

https://doi.org/10.1136/ebm.11.2.42

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In patients 40–79 years of age with hypertension and ⩾3 other cardiovascular (CV) risk factors, is amlodipine plus perindopril more effective than atenolol plus bendroflumethiazide for reducing CV outcomes?

    Clinical Impact Ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆

    METHODS

    Embedded ImageDesign

    randomised controlled trial (Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm [ASCOT-BPLA]).

    Embedded ImageAllocation

    concealed.*

    Embedded ImageBlinding

    blinded (outcome assessors).*

    Embedded ImageFollow up period

    median 5.5 years.

    Embedded ImageSetting

    686 family practices in the Nordic countries and 32 regional centres in the UK and Ireland.

    Embedded ImagePatients

    19 257 patients 40–79 years of age (mean age 63 y, 77% men) who had hypertension and ⩾3 other CV risk factors. Exclusion criteria included previous myocardial infarction (MI), currently treated angina, and a cerebrovascular event …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • For correspondence: Dr B Dahlöf, Sahlgrenska University Hospital/Östra, Göteborg, Sweden. bjorn.dahlof{at}scri.se

    • Sources of funding: Pfizer and Servier Research Group.

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2006; 11 63a-63a Published Online First: 30 Mar 2006. doi: 10.1136/ebm.11.2.63a